Abstract
Physiological studies suggest that the formamidine pesticides, chlordimeform (CDM) and N-demethylchlordimeform (DCDM), may affect octopaminergic neurotransmission. To elucidate the possible mechanism of this interaction, the present study examined in detail the biochemical effects of these compounds on a very active octopamine-sensitive adenylate cyclase present in washed particulate preparations of the firefly light organ. DCDM was a partial agonist (70% of octopamine Vmax) and was 6-fold more potent (Ka = 2.2 x 10-6 M) than octopamine (Ka = 1.4 x 10-5 M) in activating enzyme activity. At high concentrations (IC50 = 3 x 10-4 M), DCDM caused a 30% inhibition of octopamine stimulation. Activation by DCDM was reversible, nonadditive to that caused by octopamine, and could be competitively inhibited by several receptor antagonists, including cyproheptadine (Ki = 2 x 10-6 M), clozapine (Ki = 4 x 10-6 M), fluphenazine (Ki = 6 x 10-6 M), phentolamine (Ki = 1.8 x 10-5 M), and propranolol (Ki = 4.7 x 10-5 M). These inhibitory constants correlated well with those for inhibiting octopamine stimulation. The agonist activity of DCDM was specific for tissue containing an octopamine-activated adenylate cyclase; enzyme activity in the rat caudate nucleus (activated by dopamine) and in the heart and liver (activated by isoproterenol) was little affected by DCDM. In contrast to DCDM, CDM was a weak octopamine agonist (Ka = 3 x 10-5 M; 9% of octopamine Vmax) in the light organ. At higher concentrations (IC50 = 3 to 10 x 10-4 M), CDM was an octopamine antagonist, causing nearly complete inhibition of octopamine stimulation at 1 to 3 x 10-3 M. This inhibitory effect of CDM was reversible, pH-dependent, and noncompetitive with octopamine. It was also nonselective, since CDM inhibited dopamine-sensitive, beta-adrenergic-sensitive, and non-hormone-dependent adenylate cyclases in mammalian brain and liver. The above results indicate that, at low concentrations, DCDM can bind specifically and reversibly to octopamine receptors with a resultant activation of adenylate cyclase. CDM, on the other hand, has little direct effect on the octopamine receptor; its octopamimetic actions in vivo are a probable result of its conversion to DCDM. At high, nonpharmacological doses, CDM exerts noncompetitive and non-receptor-specific inhibitory effects on adenylate cyclase. These data have relevance to understanding the structural requirements necessary for interaction with octopamine-sensitive adenylate cyclase.
ACKNOWLEDGMENT We wish to thank Professor J. E. Lloyd for his help in speciating the fireflies used in this study.
- Copyright © 1981 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|